Why Amgen’s recent move is tied to earnings and pipeline news Amgen (AMGN) has been back on many investors’ screens after a strong third quarter, with double digit revenue growth and a wider mix of ...

Investing.com -- Bernstein cut its rating on Amgen Inc (NASDAQ:AMGN) to Market-Perform from Outperform, keeping its $335 price target, saying 2026 is likely to be a waiting year with limited catalysts ...

Johnson & Johnson reports Q4 earnings Jan 21 with 22% EPS growth expected. Stelara biosimilars and talc verdict weigh on ...

Compass Therapeutics, Inc. is rated a Buy with strong cash position and strong data readout by the end of 1H 2026. Read more ...

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme ...

Sun Pharma has engaged a European bank as an advisor to structure a comprehensive financial proposal that may be presented to ...

Discover tailored retirement income strategies. Learn our Income Method and two resilient, cash-generating solutions for ...

Investing in dividend stocks, which can help boost returns through dividend reinvestment, is particularly good, as they have ...

Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% ...

Adam Rogers, MD, Chairman and Interim Chief Executive Officer will be joined by members of the NervGen management team, Board of Directors, advisors, and other guests.